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The central role of phosphatidylinositol 3‑kinase (PI3K, p110a) signaling in allowing
cancer cells to bypass normal growth‑limiting controls has led to the development of
PI3K(p110a) inhibitors. A challenge in targeting PI3K(p110a) relates to the diverse
actions of the PI3K pathway in numerous cell types. Recent findings in mice deficient
in PI3K(p110a) activity in the heart, demonstrate the critical role of this pathway in
protecting the heart against pathological insults. Mice deficient in PI3K(p110a) displayed
accelerated heart failure in response to dilated or hypertrophic cardiomyopathy. These
results help explain the association of cardiomyopathy in cancer patients given tyrosine
kinase inhibitors and raise concerns for the use of PI3K(p110a) inhibitors in cancer
patients with cardiovascular risk factors. Interestingly, an inhibitor of the mammalian
target of rapamycin (a downstream effector of PI3K), did not have adverse effects on the
heart. A more complete understanding of the complex arms and interactions of the PI3K
pathway will hopefully lead to the development of anti‑cancer agents without cardiac
complications.
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Phosphatidylinositol 3‑kinases (PI3Ks) are a family of lipid kinases that phosphorylate
the hydroxyl group at position 3 of phosphatidylinositol (4,5) bisphosphate (PIP2) to
produce the second messenger phosphatidylinositol (3,4,5) trisphosphate (PIP3).1,2 PI3K
isoforms are divided into three classes (I, II, III) and composed of several subunits.1,2
Class I PI3Ks are the best characterized and are subdivided into class IA and IB. Class IA
PI3Ks consist of a catalytic subunit (p110a, p110b and p110d) and a regulatory subunit
(p85a, p55a, p50a, p85b, and p55g). They are activated by receptor tyrosine kinases
e.g., insulin and insulin‑like growth factor 1 receptors (IGF1R; Fig. 1). Other tyrosine
kinase receptors like BCR‑ABL and ErbB2, which new anti‑cancer drugs target, also signal
through the PI3K pathway.3,4 Class IB PI3K consists of the p110g catalytic subunit and
the p101 regulatory subunit and is activated by G‑protein‑coupled receptors (GPCRs;
Fig. 1). Class I PI3Ks produce PIP3, a lipid second messenger that controls a wide range
of cellular responses.5 Phosphatase and tensin homolog (PTEN) negatively regulates PI3K
signaling by dephosphorylating PIP3 to PIP2. Akt is activated downstream of PIP3 to
mediate physiologic processes. Substantial crosstalk exists with other signaling networks at
all levels of the PI3K pathway.6
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The Central Role of PI3K Signaling in Carcinogenesis
It has been suggested that malignant growth requires six essential changes in cell physiology including self‑sufficiency in growth signals, insensitivity to growth‑inhibitory signals,
evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.7 Mutations in the PI3K signaling pathway play critical roles in at least
two of these oncogenic phenotypes (i.e., self‑sufficiency in growth signals and evasion of
apoptosis). Many inherited and acquired oncogenic mutations in PI3K signaling have been
identified.6 For example, loss‑of‑function mutations of the tumour suppressor PTEN, are
found in Cowden disease, a familial cancer syndrome, and a significant percentage of
spontaneous cancers, leading to constitutive activation of class I PI3Ks.8,9 Activating
mutations of PI3K(p110a) have also been associated with diverse forms of cancer at high
frequency.10,11 Thus, uncontrolled activation of the PI3K(p110) pathway is a critical
molecular mechanism by which cancer cells bypass normal growth‑limiting controls.
Consequently, the therapeutic potential of PI3K(p110a) inhibitors has generated great
Cell Cycle
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Inhibiting PI3K(p110a) in a Setting of Heart Disease
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interest.12‑15 A challenge in targeting PI3K(p110a), however, relates
to the diverse actions of the PI3K(p110a) pathway in numerous cell
types and the theoretical off‑site effects. One such concern was the
risk of diabetes because PI3K is a downstream effector of the insulin
receptor. Later reports suggested that unmanageable metabolic
disturbances may not be a major concern.13 On the other hand, the
risk of cardiomyopathy may be significant, based on studies in mouse
models and clinical experience with tyrosine kinase inhibitors.
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Figure 1. Schematic of signaling cascades in the heart. PI3K is activated by
receptor tyrosine kinases (RTK) and G‑protein‑coupled receptors (GPCRs). In
the heart, PI3K activated by RTK induces physiological cardiac hypertrophy,
whereas PI3K activated by GPCRs participates in the depressed cardiac
function associated with pathological hypertrophy. IFG, insulin-like growth
factor 1; Ang II, angiotensin II; ET-1, endothelin 1; mTOR, mammalian target
of rapamycin; ERK, extracellular responsive kinase; PKC, protein kinase C.

UT
E

.

Cardiac function was not compromised in mice deficient in
PI3K(p110a) under basal conditions, but the critical role of
PI3K(p110a) in regulating physiological heart growth led us to
believe that inhibiting PI3K(p110a) in the heart may have an adverse
effect in the presence of pathologic stimuli. To test this hypothesis,
we recently studied dnPI3K(p110a) transgenic mice in a setting of
dilated or hypertrophic cardiomyopathy.26 DnPI3K(p110a) transgenic mice were genetically crossed to a transgenic mouse model of
dilated cardiomyopathy (DCM)27 or subjected to pressure overload
for 1 week (a surgically placed constriction of the ascending aorta
increases the pressure work of the heart to induce hypertrophic
cardiomyopathy).28 The transgenic mouse model of DCM has a
mean lifespan of approximately 80 days in males. In a setting of
reduced PI3K(p110a) activity, lifespan in the DCM model was
reduced dramatically to ~40 days.26 In the model of pressure overload, cardiac function was significantly depressed in dnPI3K(p110a)
transgenic mice but not control (non-transgenic) animals (Fig. 2A).26
These data suggest that PI3K(p110a) is essential for maintaining
cardiac function in response to a pathological cardiac insult and raises
concerns for the use of PI3K(p110a) inhibitors in cancer patients
with cardiovascular risk factors.
PI3K(p110a) induced “good” physiological cardiac growth also
appears to inhibit “bad” pathological growth and to protect the heart
from failing. In contrast to the accelerated heart failure observed in
dnPI3K transgenics subjected to dilated or hypertrophic cardiomyopathy, caPI3K transgenic mice with increased physiological heart
growth were significantly protected in these models.26 Transgenic
expression of caPI3K increased the lifespan of mice with dilated
cardiomyopathy by 15–20%. The increase was comparable to that
found using angiotensin‑converting enzyme inhibitors, a mainstay
of clinical heart failure management.27 The caPI3K transgenics also
displayed a blunted hypertrophic response to pressure overload and
less pathology than control mice.26
To understand how physiological signaling/growth inhibits
pathological growth, we isolated myocytes from non-transgenic,
caPI3K transgenic and dnPI3K transgenic hearts. caPI3K myocytes
showed a blunted response to GPCR stimulation whereas dnPI3K
myocytes showed an exaggerated response.26 These data suggest that
PI3K(p110a) can inhibit signaling molecules downstream of GPCR,
and explains how inhibition of PI3K(p110a) could accentuate the
unhealthy response to pathologic stimuli.
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Not All Growth is Bad: PI3K(p110a) Mediates
Physiologic Heart Growth and Provides Protection
from Pathologic Stress
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Growth of the heart is broadly classified as either pathological
(“bad”) or physiological (“good”).16 Cardiac growth in response to
pathologic stimuli like hypertension is a poor prognostic sign because
of its association with the development of heart failure.17,18 This
form of growth is referred to as pathologic hypertrophy. Signaling
cascades downstream of GPCR have been implicated in inducing
pathologic cardiac hypertrophy. Cardiac specific overexpression of
Gaq,19 PKCb20 and calcineurin21 lead to hypertrophy, heart failure
and premature death in transgenic mice. (Fig. 1). An exception
to the association of heart failure with hypertrophy is the cardiac
muscle growth that occurs in athletes. Physiologic growth includes
developmental and exercise‑induced heart growth and is regulated by
the IGF1R‑PI3K(p110a) pathway (Fig. 1).22‑24 Physiological cardiac
hypertrophy is associated with normal or enhanced cardiac function,
and is not associated with heart failure and increased mortality.16,25
In a cardiac‑specific transgenic mouse model expressing a constitutively active (ca) PI3K(p110a) mutant, PI3K(p110a) activity was
elevated 6.5‑fold, heart size was increased by approximately 20%,
and cardiac function and lifespan were normal.22 In contrast, in a
cardiac‑specific mouse model expressing a dominant negative (dn)
PI3K(p110a) mutant, PI3K(p110a) activity was reduced by 77%
and hearts were approximately 20% smaller. Under basal conditions,
cardiac function in dnPI3K transgenics was not significantly different
to that of control animals.22 This suggests that PI3K(p110a) inhibitors may be safe in the heart under normal conditions.
www.landesbioscience.com

Paradoxical Effects of Mammalian Target 			
Of Rapamycin (mTOR) Inhibition in the Heart
Inhibitors of mTOR, a downstream target of PI3K/Akt and
effector of the growth response, are also being developed as anti‑cancer
drugs. Encouraging results from clinical trials of mTOR inhibitors
have emerged.29 Somewhat surprisingly, rapamycin, an inhibitor of
mTOR, had an opposite effect on cardiac function to that observed
in PI3K deficient mice (i.e., dnPI3K). Rapamycin improved cardiac
function in a setting of left ventricular hypertension and cardiac
dysfunction30 (Fig. 2B). Furthermore, rapamycin reduced cardiac
fibrosis in response to pressure overload,31 whereas inhibition of
PI3K(p110a) resulted in more fibrosis, which adversely increases the
stiffness of the myocardium.26 The opposite effects of reductions in
PI3K or mTOR activity on cardiac function highlight the biological
complexity of targeting this pathway. While these results seem
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patients given tyrosine kinase or PI3K inhibitors.
These stressors might include comorbid diseases
like hypertension or other chemotherapeutic drugs
with cardiotoxic effects. In this regard, the incidence
of cardiomyopathy has declined substantially in
breast cancer patients given trastuzumab when such
issues were addressed.39 Inhibition of maladaptive
neurohormonal responses mediated by GPCR in
the stressed heart during induction of chemotherapy
could also yield important long term benefits.40
One might also prevent cardiomyopathy with
individualized or combination strategies. Clearly,
PI3K signaling is activated via multiple receptor
types in the heart. Why then do some patients given
tyrosine kinase inhibitors develop heart failure but
others do not? Perhaps these patients have deficiencies
in alternative pathways for PI3K activation or are
unusually dependent on the specific pathway being
Figure 2. (A) Cardiac function in non-transgenic (Ntg) or dnPI3K transgenic mice in response
inhibited by the prescribed tyrosine kinase inhibitor.
to a moderate model of pressure overload or the sham operation for 1 week. Cardiac function
was assessed non-invasively by echocardiography by measuring fractional shortening. If the mechanism in patients at risk could be defined,
Moderate pressure overload does not induce cardiac dysfunction in Ntg after a period of
one might be able to supplement the alternative
one week. Data taken from McMullen et al.26 (B) Cardiac function in Ntg mice subjected to a
pathway in the heart without driving the oncogenic
severe model of pressure overload or the sham operation for 1 week. Mice were then treated
pathway. Alternatively, it has been suggested that
with an mTOR inhibitor (rapamycin) or vehicle for 1 week. The severe model of pressure
concurrent inhibition of PI3K(p110a) and mTOR
overload induces cardiac dysfunction in mice after 1 week. *P<0.05, †P<0.05 compared
may be required for complete growth inhibition.12
with sham. Data taken from McMullen et al.30
To date, the effects of this treatment combination on
the heart have not been comprehensively addressed,
contradictory, it may be due to feedback mechanisms when inhibiting but experimental animal models offer the promise that adding an
mTOR. Inhibiting mTOR has been reported to result in feedback mTOR inhibitor may actually benefit the stressed heart.
In summary, recent findings in mice with deficient or supranormal
on Akt (Fig. 1), resulting in increased or decreased Akt activation
depending on the exposure time.32,33 Interestingly, Akt appears PI3K(p110a) activity in the heart demonstrate the vital role of this
to be differently regulated in the heart. Myostatin, an inhibitor of pathway in normal growth and protection against pathologic stress.
cardiac growth, inhibited GPCR induced Akt phosphorylation but The data explain the association of cardiomyopathy in patients
not receptor tyrosine kinase induced phosphorylation.34 Finally, given tyrosine kinase inhibitors as cancer chemotherapy and raise
Akt1 and 2, the predominant isoforms in the heart may mediate the concern that future PI3K(p110a) inhibitors may cause an even
separate physiologic processes induced by PI3K. Akt1 seems to effect higher incidence of heart failure. Fortunately, as the complex arms
physiologic growth and the anti‑hypertrophic response to pressure and interactions of the PI3K pathway are better understood, hope
overload, whereas Akt2 may effect anti‑apoptotic pathways in the is raised that the deleterious cardiac complications can be avoided.
heart.35,36 Rapamycin might affect a very specific arm of the PI3K Thus, patients may be offered the dual promise of a cure for their
signaling pathway that leaves intact the salutory effects of PI3K cancer and a good life.
activation in the heart.
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An incredible demand is placed upon the mammalian heart
to pump an entire lifetime without any significant mechanism to
replace injured or dead cells. Therefore, a robust mechanism must
exist to ensure survival of cardiac myocytes when they are stressed.
It is not surprising then, that cancer cells and the heart share the
PI3K pathway as a molecular survival mechanism. Considered in
this context, the association of heart failure in cancer patients given
tyrosine kinase inhibitors, like traztuzumab and imatinib mesylate,
is understandable. Trastuzumab‑related cardiomyopathy has been
linked with downregulation of ErbB2 signaling, and imatinib
mesylate is thought to promote apoptosis and heart damage by
inhibiting the non-receptor tyrosine kinase c‑Abl.37,38 Obviously,
one should not have to trade one disease for another that often has
a worse prognosis.
Since dnPI3K transgenic animals have normal cardiac function until
stressed, it seems prudent to minimize stressors on the heart in cancer
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